Dr. Deyu Sun 孙德宇
Chief Physician
Department of Radiation Oncology, Liaoning Cancer Hospital & Institute, Shenyang
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiotherapy and comprehensive treatment for nasopharyngeal, breast, lung, and rectal cancers. Focus includes intensity-modulated radiotherapy (IMRT), target delineation, organ protection, and preoperative concurrent chemoradiotherapy.
Dr. Sun is a Chief Physician in the Department of Radiation Oncology at Liaoning Cancer Hospital & Institute. Dr. Sun earned a bachelor’s degree from China Medical University in 1993, a master’s in radiation oncology in 2003, and a PhD in pathology in 2007. Dr. Sun leads two provincial research projects on lung cancer cell behavior and nasopharyngeal cancer biomarkers.
Professional roles
- Youth Member, Radiotherapy Professional Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Sun Deyu). Papers usually list the name as Deyu Sun or Sun D.
Selected publications
16 papers on PubMed matched by name and affiliation; 7 as first or senior author since 2016. Most recent first- or senior-author papers:
- BMC Cancer, 2026 (senior author): Rs12516 A allele elevates the risk of colorectal cancer via functional CeRNA network of BDNF-AS, miR-4704-5p and BRCA1. PubMed 41555274
- World J Surg Oncol, 2023 (senior author): Neuroendocrine differentiation: a risk fellow in colorectal cancer. PubMed 36899368
- World J Surg Oncol, 2022 (senior author): Prognostic value of elastic lamina staining in patients with stage III colon cancer. PubMed 36503509
- J Gene Med, 2021 (senior author): Circular RNA circ_0001588 sponges miR-211-5p to facilitate the progression of glioblastoma via up-regulating YY1 expression. PubMed 34105224
- Biol Res, 2018 (first author): MicroRNA-153-3p enhances cell radiosensitivity by targeting BCL2 in human glioma. PubMed 30537994
- Med Sci Monit, 2018 (senior author): Lapatinib, a Dual Inhibitor of Epidermal Growth Factor Receptor (EGFR) and HER-2, Enhances Radiosensitivity in Mouse Bladder Tumor Line-2 (MBT-2) Cells In Vitro and In Vivo. PubMed 30125265
- Eur J Med Chem, 2018 (senior author): Synthesis and biological evaluation of 4,6-diphenyl-2-(1H-pyrrol-1-yl)nicotinonitrile analogues of crolibulin and combretastatin A-4. PubMed 29407949
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion